Healthcare Global Enterprises Limited has informed the Exchange about Transcript of the Earnings Call held on May 20, 2026, with Analysts/Investors to discuss the Audited Financial Results (both Standalone & Consolidated) of the Company for the quarter and year ended March 31, 2026
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
HCG reported FY26 revenues of INR 2,545 crore (15% YoY growth) with Q4 revenues at INR 652 crore (11.3% YoY growth). Full year Adjusted EBITDA stood at INR 471.1 crore (19% YoY growth) with margins improving by 70 bps to 18.5%. The company completed a rights issue raising INR 425 crore and reduced net debt to 1.4x from 2.2-2.3x earlier. Key strategic actions include the sale of Milann (fertility business) to Inviga Healthcare Fund for INR 63 crore enterprise valuation, commencement of North Bangalore facility with MR-Linac technology, and plans to add 200+ beds across Cuttack, Vizag, Ranchi, and Bhavnagar over 24 months. Management targets 1,000 bed additions by FY30 (600 brownfield, 400 greenfield) and aims for 20% ROCE in 4-5 years. Kenya operations delivered strong 71% revenue growth in FY26.
The focus on oncology through Milann divestment, margin expansion demonstrated (90 bps improvement in Q4), and strengthened balance sheet position HCG well for profitable growth. The targeted 15% revenue growth for FY27 remains achievable through multiple levers including North Bangalore ramp-up, brownfield expansions, and clinical talent additions.